Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A topical combination antibiotic medication containing clindamycin and sodium sulfacetamide. Clindamycin is a lincosamide antibiotic that works by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, exerting a bacteriostatic effect. Sodium sulfacetamide is a sulfonamide antibiotic that inhibits bacterial synthesis of folic acid by blocking the enzyme dihydropteroate synthase, which is essential for bacterial growth and reproduction. This combination targets multiple pathogenic factors in skin conditions, particularly acne vulgaris, by reducing populations of acne-causing bacteria such as *Cutibacterium acnes* (formerly *Propionibacterium acnes*) and *Staphylococcus* species. The combination is often formulated with tretinoin to provide complementary mechanisms targeting bacterial proliferation, inflammation, and comedone formation. This medication is typically available in concentrations of clindamycin 1% and sodium sulfacetamide 5% in various topical formulations including gels, lotions, and creams.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + sodium sulfacetamide.